Dexmedetomidine is an a2-adrenergic receptor agonist with an eight-fold greater affinity for the a2-adrenergic receptor than its sister drug clonidine. It is a sedative that is clear, colourless and tasteless and has been used in children for a number of years. Advantages of Dexmedetomidine over other agents used in paediatrics include: ease of administration; reduction in postoperative analgesic requirements; and reduction in postoperative nausea and vomiting (PONV).
Recent Posts
- A Scoping Review of the Mechanisms Underlying Developmental Anesthetic Neurotoxicity
- 2025 Annual Meeting, presented by the International Anesthesia Research Society (IARS) and the Society of Critical Care Anesthesiologists (SOCCA), March 20 – 23, 2025, Honolulu, HI
- Exposure to Operative Anesthesia in Childhood and Subsequent Neurobehavioral Diagnoses: A Natural Experiment Using Appendectomy
- Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial. Claire Elizabeth Wainwright, et al. June 2024
- Columbia University Physician Scientist and SmartTots Investigator, Caleb Ing, MD, publishes new findings regarding prenatal exposure to general anesthesia and subsequent risk to the child.